{"analyses":[{"ciLowerLimit":"0.12","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.86","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2655","paramType":"Hazard Ratio (HR)","paramValue":"0.46","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.75","upperLimit":"0.98","value":"0.93"},{"groupId":"OG001","lowerLimit":"0.74","upperLimit":"0.98","value":"0.93"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.59","upperLimit":"0.91","value":"0.80"},{"groupId":"OG001","lowerLimit":"0.74","upperLimit":"0.98","value":"0.93"}]}],"title":"12 months"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.54","upperLimit":"0.88","value":"0.76"},{"groupId":"OG001","lowerLimit":"0.69","upperLimit":"0.96","value":"0.89"}]}],"title":"18 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"30"}],"units":"Participants"}],"description":"Relapse-free survival assesses the clinical benefit of remaining in remission free from relapse or death due to the disease. It was defined as the time from transplant to relapse or death due to the disease. Relapse following complete response was defined as reappearance of leukemic blasts in the peripheral blood or finding more than 5% blasts in the bone marrow.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients received standard of care in the post stem cell transplant (SCT) setting in addition to Midostaurin 50mg twice a day for 12 months (cycles).","id":"OG000","title":"Standard of Care With Midostaurin"},{"description":"Patients received standard of care alone in the post SCT setting","id":"OG001","title":"Standard of Care"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"date of transplant up to 18 months","title":"Proportion of Participants With Relapse Free Survival (RFS) up to 18 Months Post Transplant (Full Analysis Set) by Kaplan-Meier Analysis","type":"PRIMARY","unitOfMeasure":"proportion of participants"}